Extramedullary disease in multiple myeloma: a systematic literature review

J Bladé, M Beksac, J Caers, A Jurczyszyn… - Blood Cancer …, 2022 - nature.com
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive
form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to …

Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection

A Allegra, A Tonacci, R Sciaccotta, S Genovese… - Cancers, 2022 - mdpi.com
Simple Summary Multiple myeloma is a malignant neoplasm of plasma cells with complex
pathogenesis. With major progresses in multiple myeloma research, it is essential that we …

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma

LJ Costa, S Chhabra, E Medvedova… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

The evolving view of thermogenic fat and its implications in cancer and metabolic diseases

X Yin, Y Chen, R Ruze, R Xu, J Song… - Signal Transduction and …, 2022 - nature.com
The incidence of metabolism-related diseases like obesity and type 2 diabetes mellitus has
reached pandemic levels worldwide and increased gradually. Most of them are listed on the …

Comparison of MRI features of fat fraction and ADC for early treatment response assessment in participants with multiple myeloma

V Koutoulidis, E Terpos, N Papanikolaou, S Fontara… - Radiology, 2022 - pubs.rsna.org
Background An imaging-based predictor of response could provide prognostic information
early during treatment course in patients with multiple myeloma (MM). Purpose To …

Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT

FE Lecouvet, MC Vekemans, T Van Den Berghe… - Skeletal radiology, 2022 - Springer
Bone imaging has been intimately associated with the diagnosis and staging of multiple
myeloma (MM) for more than 5 decades, as the presence of bone lesions indicates …

Circulating tumour cells, cell free DNA and tumour-educated platelets as reliable prognostic and management biomarkers for the liquid biopsy in multiple myeloma

A Allegra, G Cancemi, G Mirabile, A Tonacci… - Cancers, 2022 - mdpi.com
Simple Summary Even though the presently employed biomarkers in the detection and
management of multiple myeloma are demonstrating encouraging results, the mortality …

99mTc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of …

L Shi, B Chen, T Liu, L Li, B Hu, C Li, B Jia… - Molecular …, 2022 - ACS Publications
Daratumumab (DARA) is an anti-CD38 monoclonal antibody for the treatment of multiple
myeloma (MM). The tumor CD38 expression level is one of the important factors in …

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in multiple myeloma: clinical experience

U Elboga, E Sahin, YB Cayirli, M Okuyan, G Aktas… - Tomography, 2022 - mdpi.com
Objective: In this study, we aimed to compare [68Ga] FAPI PET/CT and [18F] FDG PET/CT
imaging to detect lesions in multiple myeloma. Methods: A total of 14 patients with multiple …

[HTML][HTML] Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma-a potential imaging biomarker for disease prognosis

S Kraus, P Klassen, M Kircher, A Dierks… - Theranostics, 2022 - ncbi.nlm.nih.gov
Beyond being a key factor for tumor growth and metastasis in human cancer, CXC motif
chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells …